For the quarter ending 2025-09-30, FLGT had $62,497K increase in cash & cash equivalents over the period. -$41,089K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from consolidated operations | -37,981 | - |
| Equity-based compensation | 30,306 | - |
| Depreciation and amortization | 18,011 | - |
| Adjustment for credit losses | 5,794 | - |
| Noncash lease expense | 1,197 | - |
| (gain) loss on disposal of fixed asset | 3 | - |
| Amortization of discount of marketable securities | 4,161 | - |
| Deferred taxes | -1,110 | - |
| Unrecognized tax benefits | -437 | - |
| Net realized (gain) loss on marketable securities | 21 | - |
| Impairment loss | 9,926 | - |
| Other | -34 | - |
| Trade accounts receivable | 7,874 | - |
| Income tax | -33,056 | - |
| Other current and long-term assets | 1,025 | - |
| Accounts payable | -374 | - |
| Contract liabilities | 75 | - |
| Customer deposits | 923 | - |
| Accrued liabilities and other liabilities | -3,414 | - |
| Operating lease liabilities | -1,179 | - |
| Net cash used in operating activities | -23,495 | - |
| Maturities of marketable securities | 132,910 | - |
| Proceeds from sale of marketable securities | 0 | - |
| Proceeds from sale of fixed assets | 5 | - |
| Purchase of marketable securities | 18,879 | - |
| Purchases of fixed assets | 17,594 | - |
| Acquisition of businesses, net of cash | -3,775 | - |
| Net cash provided by (used in) investing activities | 100,217 | - |
| Repurchase of common stock | 10,884 | - |
| Common stock withholding for employee tax obligations | 2,589 | - |
| Repayment of notes payable | 471 | - |
| Principal paid for finance lease | 311 | - |
| Net cash used in financing activities | -14,255 | - |
| Effect of exchange rate changes on cash and cash equivalents | 30 | - |
| Restricted cash and cash equivalents, total | - | 135 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 62,497 | - |
| Cash and cash equivalents, at carrying value, ending balance | - | 87,880 |
| Cash and cash equivalents at beginning of period | 55,279 | - |
| Cash and cash equivalents at end of period | 117,776 | 88,015 |
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)